生脉注射液与复方丹参注射液治疗冠心病心绞痛有效性及安全性的Meta分析

摘要

目的 考察生脉注射液与复方丹参注射液治疗冠心病心绞痛的有效性及安全性.方法计算机检索Cochrane图书馆临床对照试验资料库(2010年第3期)、Pubmed(1966年至2010年9月)、Embase( 1966年至2010年9月)、中国(CNKI)学术文献总库(1979年至2010年9月)、万方数字化期刊库(1981年至2010年9月)、中文科技期刊数据库(1989年至2010年9月),按纳入与排除标准选择随机对照试验、评价质量,提取资料,并用RevMan 4.2软件对数据进行Meta分析.结果共初检出964篇文献,经筛选最终纳入8篇关于生脉注射液与复方丹参注射液治疗冠心病心绞痛的随机对照研究.以心绞痛及心电图为疗效尺度.生脉组与复方丹参组疗效比较,差异有统计学意义.复方丹参组有6例出现不良反应,症状轻微.生脉组无明显不良反应.结论生脉注射液较复方丹参注射液治疗冠心病心绞痛更安全有效.%Objective:To approach the efficacy and safety of Shengmai Injection and Compound Danshen Injection in angina pectoris. Methods: Electronic searches were performed using the Cochrane Central Register of Controlled Trials (Issue3,2010),MEDLINE (1966 to September 2010),Embase (1966 to September 2010),CNKI (1979 to September 2010) .Wanfang (1981-2010.09),VIP (1989-2010.09). Randomized controlled trials (RCTs) were screened the retrieved studies according to predefined inclusion and exclusion criteria. The quality of included studies was evaluated and used by RevMan 4.2 software for meta analysis. Results: 8 papers from 964 articles were finally included. Therapeutic effects of angina pectoris and ECG effective selected as the study indices. There were some statistical differences between the Shengmai Injection group and the Compound Danshen Injection group. Meanwhile,6 cases of the adverse reaction,which were mild symptoms,were in the Compound Danshen Injection group. However,no obvious adverse reaction was in the Shengmai Injection group. Conclusion: Shengmai Injection is more effective and safer than Compound Danshen Injection in treating angina pectoris.